No significant impact on imputed arterial partial pressure of oxygen to fraction of inspired oxygen ratio at seven days<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, March 16, 2022 (HealthDay News) — Administration of losartan to hospitalized patients with COVID-19 and acute lung injury is not efficacious for reducing lung injury, according to a study published online March 16 in JAMA Network Open<\/em>.<\/p>\n Michael A. Puskarich, M.D., from the University of Minnesota in Minneapolis, and colleagues examined the efficacy of losartan for reducing lung injury in hospitalized patients with COVID-19 in a blinded, placebo-controlled trial conducted at 13 U.S. hospitals. Two hundred five hospitalized patients with COVID-19 and a respiratory sequential organ failure assessment score of at least 1 and not already using a renin-angiotensin-aldosterone system (RAAS) inhibitor were randomly assigned to either losartan or placebo (101 and 104 participants, respectively).<\/p>\n The researchers found that losartan did not significantly affect the imputed arterial partial pressure of oxygen to fraction of inspired oxygen ratio at seven days compared with placebo (difference, \u00e2\u0088\u009224.8; 95 percent confidence interval, \u00e2\u0088\u009255.6 to 6.1; P = 0.12). Losartan did not improve any secondary outcomes compared with placebo, and resulted in fewer vasopressor-free days than placebo (median, 9.4 versus 8.7).<\/p>\n “The results of this study do not support the hypothesis that losartan effectively mitigates viral-induced acute lung injury in COVID-19, with uncertain implications for other, potentially more potent, agents that target the RAAS,” the authors write. “This study further contributes to the literature in this field.”<\/p>\n